MaxWell has successfully patented key innate immune system mimetics.
MaxWell’s Heterochronic Optimized Plasma Exchange (HOPE) for Alzheimer’s clinical trial is set to begin
in early 2018. The team (big data, Mayo Clinic, Stanford) are remarkable entrepreneurs and scientists.
Key research funding from US DOE, NIH, NorthWestern, UCBerkeley, Stanford.


MaxWell is about creating health, not just fighting disease. We seek to optimize cognitive performance and healthspan as well as reverse degenerative conditions like Alzheimer’s, Parkinson’s, and others.